Article thumbnail

Recent Progress in Gene Therapy for Ovarian Cancer

By Ángela Áyen, Yaiza Jiménez Martínez, Juan A. Marchal and Houria Boulaiz

Abstract

Ovarian cancer is the most lethal gynecological malignancy in developed countries. This is due to the lack of specific symptoms that hinder early diagnosis and to the high relapse rate after treatment with radical surgery and chemotherapy. Hence, novel therapeutic modalities to improve clinical outcomes in ovarian malignancy are needed. Progress in gene therapy has allowed the development of several strategies against ovarian cancer. Most are focused on the design of improved vectors to enhance gene delivery on the one hand, and, on the other hand, on the development of new therapeutic tools based on the restoration or destruction of a deregulated gene, the use of suicide genes, genetic immunopotentiation, the inhibition of tumour angiogenesis, the alteration of pharmacological resistance, and oncolytic virotherapy. In the present manuscript, we review the recent advances made in gene therapy for ovarian cancer, highlighting the latest clinical trials experience, the current challenges and future perspectives

Topics: ovarian cancer, gene therapy, delivery systems, promoter, suicide genes, ovarian cancer stem cells, Biology (General), QH301-705.5, Chemistry, QD1-999
Publisher: MDPI AG
Year: 2018
DOI identifier: 10.3390/ijms19071930
OAI identifier: oai:doaj.org/article:1f29f93043ae443c8950f02d49a6f85a
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.mdpi.com/1422-0067/... (external link)
  • https://doaj.org/article/1f29f... (external link)
  • https://doaj.org/toc/1422-0067 (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.